Sionna Therapeutics (NASDAQ:SION) Issues Quarterly Earnings Results

Sionna Therapeutics (NASDAQ:SION) posted its quarterly earnings results on Thursday. The company reported ($3.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.68) by ($0.70), Zacks reports.

Sionna Therapeutics Stock Down 1.4 %

SION stock opened at $13.69 on Friday. Sionna Therapeutics has a 1 year low of $11.95 and a 1 year high of $25.19.

Analysts Set New Price Targets

Several research firms have issued reports on SION. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price target for the company. TD Cowen initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating for the company. Finally, Guggenheim initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price for the company.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.